Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J C Fleishaker

Showing results (11-20 of 72) with videos related to

Pageof 8
Sort By:
Pharmaceutical Research|April 1, 1992
Pharmacokinetic and pharmacodynamic comparison of immediate-release and sustained-release adinazolam mesylate tablets after single- and multiple-dose administrationJ C Fleishaker, C E Wright
Psychopharmacology|January 1, 1989
Adinazolam pharmacokinetics and behavioral effects following administration of 20-60 mg oral doses of its mesylate salt in healthy volunteersJ C Fleishaker, J P Phillips
International Journal of Clinical Pharmacology and Therapeutics|June 6, 2000
Pharmacokinetics of reboxetine in elderly patients with depressive disordersI Poggesi, C Pellizzoni, J C Fleishaker
Journal of Pharmaceutical Sciences|March 1, 1987
Factors affecting the milk-to-plasma drug concentration ratio in lactating women: physical interactions with protein and fatJ C Fleishaker, N Desai, P J McNamara
Pharmaceutical Research|February 1, 1991
Extent and variability of the first-pass elimination of adinazolam mesylate in healthy male volunteersJ C Fleishaker, H Friedman, S R Pollock
Journal of Pharmaceutical Sciences|February 1, 1989
Possible effect of lactational period on the milk-to-plasma drug concentration ratio in lactating women: results of an in vitro evaluationJ C Fleishaker, N Desai, P J McNamara
Journal of Pharmaceutical Sciences|April 1, 1997
Pharmacokinetics of tirilazad and U-89678, an active, reduced metabolite, following acute head trauma in adultsJ C Fleishaker, R N Straw, C J Cross
International Journal of Clinical Pharmacology and Therapeutics|May 1, 1994
Multiple-dose tolerability and pharmacokinetics of tirilazad mesylate at doses of up to 10 mg/kg/day administered over 5-10 days in healthy volunteersJ C Fleishaker, L K Hulst, G R Peters
Clinical Pharmacology and Therapeutics|October 1, 1994
The effect of phenytoin on the pharmacokinetics of tirilazad mesylate in healthy male volunteersJ C Fleishaker, L K Hulst, G R Peters
Clinical Pharmacology and Therapeutics|November 5, 1999
Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humansB D Herman, J C Fleishaker, M T Brown
Pageof 8

Showing results (11-20 of 72) with videos related to

Sort By:
Pageof 8
Pharmaceutical Research|April 1, 1992
Pharmacokinetic and pharmacodynamic comparison of immediate-release and sustained-release adinazolam mesylate tablets after single- and multiple-dose administrationJ C Fleishaker, C E Wright
Psychopharmacology|January 1, 1989
Adinazolam pharmacokinetics and behavioral effects following administration of 20-60 mg oral doses of its mesylate salt in healthy volunteersJ C Fleishaker, J P Phillips
International Journal of Clinical Pharmacology and Therapeutics|June 6, 2000
Pharmacokinetics of reboxetine in elderly patients with depressive disordersI Poggesi, C Pellizzoni, J C Fleishaker
Journal of Pharmaceutical Sciences|March 1, 1987
Factors affecting the milk-to-plasma drug concentration ratio in lactating women: physical interactions with protein and fatJ C Fleishaker, N Desai, P J McNamara
Pharmaceutical Research|February 1, 1991
Extent and variability of the first-pass elimination of adinazolam mesylate in healthy male volunteersJ C Fleishaker, H Friedman, S R Pollock
Journal of Pharmaceutical Sciences|February 1, 1989
Possible effect of lactational period on the milk-to-plasma drug concentration ratio in lactating women: results of an in vitro evaluationJ C Fleishaker, N Desai, P J McNamara
Journal of Pharmaceutical Sciences|April 1, 1997
Pharmacokinetics of tirilazad and U-89678, an active, reduced metabolite, following acute head trauma in adultsJ C Fleishaker, R N Straw, C J Cross
International Journal of Clinical Pharmacology and Therapeutics|May 1, 1994
Multiple-dose tolerability and pharmacokinetics of tirilazad mesylate at doses of up to 10 mg/kg/day administered over 5-10 days in healthy volunteersJ C Fleishaker, L K Hulst, G R Peters
Clinical Pharmacology and Therapeutics|October 1, 1994
The effect of phenytoin on the pharmacokinetics of tirilazad mesylate in healthy male volunteersJ C Fleishaker, L K Hulst, G R Peters
Clinical Pharmacology and Therapeutics|November 5, 1999
Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humansB D Herman, J C Fleishaker, M T Brown
Pageof 8